Genuine Biotech Delegation Visited the Third People's Hospital of Shenzhen, Proposing to Enhance Cooperation in the Antiviral Field

On Apr. 19, Wan Yuanhao and He Binyuan, vice presidents of Genuine Biotech, made a team visit to the Third People's Hospital of Shenzhen (hereinafter referred to as the "TPHSZ") and had in-depth conversations with Prof. Lu Hongzhou, president of the hospital and a fellow of American Academy of Microbiology. In hope of satisfying unmet global clinical needs with safer and more efficient treatment options, both parties agreed to seek closer cooperation in the antiviral field.

Wan Yuanhao gave Lu Hongzhou a detailed introduction to the product pipeline and R&D progress at Genuine Biotech and emphasized the company's unremitting endeavor toward the antiviral field. He also expressed heartfelt appreciation to Lu Hongzhou's team for their remarkable contributions to the project of Azvudine for the treatment of COVID-19 by presenting him a banner and a certificate on behalf of the project team (consisting of Henan Normal University, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, and Genuine Biotech).

Lu Hongzhou extended a warm welcome to the Genuine Biotech delegation and explained the great significance of the TPHSZ as the National Clinical Research Center for Infectious Diseases. He planned to launch more projects with clinical value in the future, full of expectations for future cooperation with Genuine Biotech in the antiviral field.

It is reported that the project "Development and Application of Azvudine Tablets for the Treatment of COVID-19", for its originality and social significance, won the first prize of Henan Provincial Technical Invention Award, the highest award for scientific and technological achievements in Henan province.

As one of the project leaders in the Phase III clinical trial of Azvudine Tablets for the treatment of COVID-19, Lu Hongzhou, together with his team, devoted relentless efforts during the trial to ensure the quality of the research. They played a central role in the success of the research.

As one of the main participants and contributors of the project, Lu Hongzhou won the first prize of Henan Provincial Technical Invention Award granted by the Henan Provincial People's Government.

Lu Hongzhou is a member of the Expert Committee on Disease Prevention and Control and the Expert Committee on Infection Prevention and Control in Medical Institutions of the National Health Commission, a member of the National COVID-19 Treatment Expert Group and the support team for Overseas COVID-19 Expert Group, head of the first Public Health Expert Group for Epidemic Prevention and Control in Shenzhen, and the president of the TPHSZ. He was conferred such honors, titles, and grants as "Changjiang Scholar" by the Ministry of Education, "Millions of Talent Projects, National Candidates", special government allowances from the State Council, "Young and Middle-aged Expert with Outstanding Contributions" and "Renowned Doctor of the People" by the People's Daily Health App.

In 2003, Lu Hongzhou worked on the treatment of SARS patients; in 2013, he discovered the world's first case of theavian influenza A(H7N9) virus infections in humans.